225 related articles for article (PubMed ID: 33964453)
1. Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity.
Hong GJ; Stinnett SS; Freedman SF; Wallace DK; Prakalapakorn SG
J AAPOS; 2021 Jun; 25(3):177-180. PubMed ID: 33964453
[TBL] [Abstract][Full Text] [Related]
2. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
[TBL] [Abstract][Full Text] [Related]
3. Five-Year Clinical Outcomes of Intravitreal Bevacizumab Versus Laser Photocoagulation for ROP.
Moinul P; Nanji K; Barbosa J; Sarohia GS; Fung M; Isaza G; Chaudhary V
J Pediatr Ophthalmol Strabismus; 2024; 61(1):73-74. PubMed ID: 38306241
[No Abstract] [Full Text] [Related]
4. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
5. Very late-onset reactivation of retinopathy of prematurity post anti-VEGF bevacizumab treatment for type 1 ROP: a case report.
Taylor K; Ghergherehchi L; Rao P; Harper CA; Chang E
J AAPOS; 2021 Jun; 25(3):180-184. PubMed ID: 33964455
[TBL] [Abstract][Full Text] [Related]
6. Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab.
Barry GP; Tauber KA; Fisher M; Greenberg S; Zobal-Ratner J; Binenbaum G
J AAPOS; 2019 Oct; 23(5):260.e1-260.e4. PubMed ID: 31513902
[TBL] [Abstract][Full Text] [Related]
7. Quantitative comparison of blood vessel changes after treatment of retinopathy of prematurity with laser versus bevacizumab.
Wang W; Hong GJ; Stinnett SS; Freedman SF; Wallace DK; Prakalapakorn SG
J AAPOS; 2022 Dec; 26(6):323-326. PubMed ID: 36152755
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
Erol N; Gürsoy H; Sahin A; Basmak H
J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
[TBL] [Abstract][Full Text] [Related]
9. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
10. One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity.
Kıran Yenice E; Petriçli İS; Kara C
Int Ophthalmol; 2023 Jul; 43(7):2197-2202. PubMed ID: 36522564
[TBL] [Abstract][Full Text] [Related]
11. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
12. Morphological outcome and indication for laser following intravitreal bevacizumab monotherapy for posterior retinopathy of prematurity.
Sindal MD; Nagesha CK; Yadav D; Fazal R
Lasers Med Sci; 2022 Jul; 37(5):2501-2508. PubMed ID: 35106690
[TBL] [Abstract][Full Text] [Related]
13. Reactivation of retinopathy of prematurity six years after intravitreal injection of bevacizumab.
Yasin A; Sinha S; Smith R; Jain SF; Hejkal T; Rychwalski P
J AAPOS; 2023 Aug; 27(4):236-239. PubMed ID: 37451499
[TBL] [Abstract][Full Text] [Related]
14. Timing of laser following intravitreal anti-vascular endothelial growth factor injections for aggressive posterior zone 1 retinopathy of prematurity.
Vinekar A
Indian J Ophthalmol; 2021 Aug; 69(8):1988-1989. PubMed ID: 34304161
[No Abstract] [Full Text] [Related]
15. Prospective clinical study of two different treatment regimens of combined laser photocoagulation and intravitreal bevacizumab for retinopathy of prematurity: the Indian Twin Cities ROP Study (ITCROPS) database report number 9.
Laveti V; Balakrishnan D; Rani PK; Mohamed A; Jalali S
Int Ophthalmol; 2020 Dec; 40(12):3539-3545. PubMed ID: 32776299
[TBL] [Abstract][Full Text] [Related]
16. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
[TBL] [Abstract][Full Text] [Related]
17. [Epidemiology and treatment of retinopathy of prematurity. The Hannover data in the Retina.net ROP registry from 2001-2017].
Akman SH; Pfeil JM; Stahl A; Ehlers S; Böhne C; Bohnhorst B; Framme C; Brockmann D; Bajor A; Jacobsen C; Hufendiek K; Pielen A;
Ophthalmologe; 2022 May; 119(5):497-505. PubMed ID: 34811591
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.
Sato T; Wada K; Arahori H; Kuno N; Imoto K; Iwahashi-Shima C; Kusaka S
Am J Ophthalmol; 2012 Feb; 153(2):327-333.e1. PubMed ID: 21930258
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity.
Murakami T; Sugiura Y; Okamoto F; Okamoto Y; Kato A; Hoshi S; Nagafuji M; Miyazono Y; Oshika T
Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2849-2855. PubMed ID: 33744981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
